Abstract PS5-03-09: Trial in progress: A phase 2/3 trial of iza-bren (BMS986507/BL-B01D1), an EGFRxHER3 antibody-drug conjugate, vs standard-of-care chemotherapy in patients with previously untreated, locally advanced, recurrent inoperable, or metastatic triple negative breast cancer ineligible for anti-PD-(L)1 treatment (IZABRIGHT-Breast01)
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Peter MacCallum Cancer Centre, Latin American Cooperative Oncology Group (LACOG), Samsung Medical Center, Sungkyunkwan University, German Breast Group, University of Milan, European Institute of Oncology, Bristol-Myers Squibb (United States), Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7130689448
Cites:
Cited by:
Related to: